FDA approves Givlaari, first treatment for acute hepatic porphyria

The FDA approved Givlaari for the treatment of adults with acute hepatic porphyria, a rare genetic disorder that leads to buildup of toxic porphyrin molecules that form during the production of heme.“This buildup can cause acute attacks, known as porphyria attacks, which can lead to severe pain and paralysis, respiratory failure, seizures and mental status changes. These attacks occur suddenly and can produce permanent neurological damage and death,” Richard Pazdur, MD, director of the FDA’s Oncology Center of Excellence and acting director of the Office of OncologicRead More

Share on facebook
Share on twitter
Share on linkedin